Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
November 28 2018 - 8:30AM
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX)
announced today the recent publication of an article titled:
“Apabetalone downregulates factors and pathways associated with
vascular calcification” in Atherosclerosis, the official
peer-reviewed scientific journal of the European Atherosclerosis
Society.
“Apabetalone and its unique mechanism of action
of select inhibition of BET proteins has consistently illustrated
beneficial effects on key markers of vascular risk including
calcification,” stated Dr. Kam Kalantar-Zadeh, Chief of the
Division of Nephrology and Hypertension at the University of
California, Irvine, and member of the Company’s clinical steering
and advisory boards. “In patients with high-risk cardiovascular
disease, diabetes, chronic kidney and neurodegenerative diseases,
vascular calcification is an important risk factor that we should
continue to target. This important research and publication further
helps our understanding of how select BET inhibition, via
apabetalone, could potentially help many patients who continue to
suffer under the significant burden of vascular
calcification.”
Publication Highlights
include:
- Bromodomain and extraterminal (“BET”) proteins are implicated
in vascular smooth muscle cell (VSMC) calcification (calcium
deposits in blood vessels).
- Seven specific transcription factors (“TFs”) were identified
that may cooperate with BET protein BRD4 to promote
calcification.
- Apabetalone, the Company’s BET inhibitor currently in a Phase 3
clinical trial (“BETonMACE”), prevents calcification by regulating
VSMC gene expression making it a promising therapeutic for
pathological vascular calcification.
Publication Background and
Conclusions:
Apabetalone is an inhibitor of BET proteins. In
previous clinical trials, apabetalone reduced the incidence of
major adverse cardiac events (“MACE”) in patients with
cardiovascular disease and reduced circulating factors that promote
vascular calcification (“VC”). Because VC contributes to MACE,
effects of apabetalone on pro-calcific processes were examined.
Apabetalone counters calcification of VSMCs via
an epigenetic mechanism. The findings, combined with evidence from
clinical trials, support further development of apabetalone as a
therapeutic for VC.
The full publication can be viewed using the
following LINK.
Vascular Calcification – One Process Underlying Many
Indications
The positive impact of apabetalone treatment on
countering the development and progression of VC not only supports
the ongoing Phase 3 clinical trial for high-risk cardiovascular
disease, BETonMACE, but provides evidence for its potential benefit
to patients with chronic kidney disease and neurodegenerative
disease.
Based on Company estimates, combined,
cardiovascular disease, chronic kidney disease and
neurodegenerative disease represent ~12 million high-risk patients
in the top 8 markets, and billions of dollars in healthcare
expenditures. Reducing the burden of VC could allow millions of
people to lead longer, healthier lives.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is a BET inhibitor selective for
the second bromodomain (BD2) within the BET proteins. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease, diabetes mellitus,
chronic kidney disease, end-stage renal disease treated with
hemodialysis, neurodegenerative disease, Fabry disease, peripheral
artery disease and other orphan diseases, while maintaining a well
described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations Email: ir@resverlogix.com Phone:
403-254-9252Or visit our website: www.resverlogix.com
This news release may contain certain
forward-looking information as defined under applicable Canadian
securities legislation, that are not based on historical fact,
including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should",
"expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward
looking information relating to the estimated number of high-risk
patients in the top 8 markets and the potential role of apabetalone
in the treatment of CVD, DM, chronic kidney disease, end-stage
renal disease treated with hemodialysis, neurodegenerative disease,
Fabry disease, and Orphan diseases. Our actual results, events or
developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no
assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject
to numerous assumptions and risk factors including those discussed
in our Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this
news release are expressly qualified by this cautionary statement
and are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024